Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
vedaprofen
VETCOOL B.V.
QM01AE90
vedaprofen
Horses
Anti inflammatory and antirheumatic products
Reduction of inflammation and relief of pain associated with musculoskeletal disorders and soft-tissue lesions (traumatic injuries and surgical trauma). In cases of anticipated surgical trauma, Quadrisol can be given prophylactically at least three hours prior to elective surgery.,
Revision: 18
Authorised
1997-12-04
13 B. PACKAGE LEAFLET 14 PACKAGE LEAFLET: QUADRISOL 100 MG/ML ORAL GEL FOR HORSES 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: VETCOOL B.V. Otto Hahnweg 24 3542 AX Utrecht NETHERLANDS Manufacturers responsible for batch release: Purna Pharmaceuticals N.V. Rijksweg 17 B-2870 Puurs BELGIUM 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Quadrisol 100 mg/ml oral gel for horses. 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Vedaprofen: 100 mg/ml Propylene glycol: 130 mg/ml 4. INDICATION(S) Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma). In cases of anticipated surgical trauma, Quadrisol can be given prophylactically at least 3 hours prior to elective surgery 5. CONTRAINDICATIONS Do not use in animals suffering from alimentary tract disorders, impaired heart, liver and kidney function. Do not use in foals under the age of 6 months. Do not use in lactating mares. Quadrisol must not be given with other NSAIDs or glucocorticosteroids. Do not use in the case of hypersensitivity to the active substance or to any of the excipients. 6. ADVERSE REACTIONS Typical non-steroidal anti-inflammatory drugs (NSAIDs) side effects such as lesions and bleedings in the alimentary tract, diarrhoea, urticaria, lethargy, inappetence. If symptoms occur, treatment should be discontinued. Symptoms are reversible. Overdosing may lead to death of treated animals. If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 15 7. TARGET SPECIES Horse. 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Quadrisol is intended for twice daily administration. The advised dosage is an initial dose of 2 mg/kg (2.0 ml/100 kg) followed by a maintenance dose of 1 mg/kg (1.0 ml/100 k Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Quadrisol 100 mg/ml oral gel for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Quadrisol oral gel contains: ACTIVE SUBSTANCE: Vedaprofen: 100 mg EXCIPIENTS: Propylene glycol: 130 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral gel 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Horse. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma). In cases of anticipated surgical trauma, Quadrisol can be given prophylactically at least 3 hours prior to elective surgery. 4.3 CONTRAINDICATIONS Do not use in animals suffering from alimentary tract disorders, impaired heart, liver and kidney function. Do not use in foals under the age of 6 months. Do not use in lactating mares. Do not use in the case of hypersensitivity to the active substance or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Horses intended for racing and competition should be treated according to local requirements. Appropriate precautions must be taken for such horses to ensure compliance with competition regulations. In case of doubt, it is advisable to test the urine. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals If side effects occur, treatment should be discontinued. Horses with oral lesions should be assessed clinically and the attending veterinarian should take a decision as to whether treatment should be continued. If oral lesions persist, treatment should be discontinued. Horses should be monitored for oral lesions during treatment. Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there may be potential risk of increased renal toxicity. 3 Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental ingestion, seek medical advice imme Lesen Sie das vollständige Dokument